Philogen S.p.A. (PHIL) Earnings Call Transcripts

Philogen S.p.A.'s Latest Earnings Call - March 30, 2026

Philogen S.p.A. reported its full-year results for 2025 on March 30, 2026, highlighting a net profit of approximately EUR 230 million and cash equivalents of EUR 380 million. The company is on track for a July 2026 resubmission of its marketing authorization application for Nidlegy, following positive feedback from regulatory authorities. Despite some setbacks in clinical trials, management remains optimistic about their expanding pipeline and ongoing collaborations, which could drive future growth.

Reported metrics

Guidance from management

Philogen aims to maintain a stable cash burn while expanding its clinical trials and product pipeline. The company expects to resubmit Nidlegy in July 2026, with a decision anticipated by mid-2027.

What management said

Okay. Welcome, everybody, to this new event. Today, we focus on the full year results of 2025 both from a scientific and financial perspective. As always, on. The call, we have Professor Dario Neri, our CEO and CFO, and Dr. Laura Baldi, our Chief Financial Officer; and myself, here as the Head of Investor Relator. And we're happy to guide you through the presentation lasting about 30 minutes, which is recorded and w...

think it's higher, honestly, in real life, [indiscernible] is 25% to 30% of tumor types in soft tissue sarcoma, which is a basket of many different indications. So my number would be 70%. These are very well-documented proportions. So I think this certainly corresponds to the majority of soft tissue sarcomas and having a survival signal with a few patients really enjoy very long benefit is a good starting point. And ...

What analysts pressed on

Analysts expressed concerns regarding the company's buyback program, questioning the significant gap between authorized buyback amounts and actual repurchases. Additionally, there were inquiries about the implications of clinical trial setbacks on future partnerships and product development.

Main topics on the call

• Nidlegy Resubmission Progress — Management confirmed that they are preparing for a resubmission of the Nidlegy marketing authorization application in July 2026, after addressing both CMC and clinical requests from regulatory bodies. Dario Neri stated, ...
• Clinical Trial Updates — Philogen has launched multiple new trials in 2026, including those for Nidlegy and Fibromun, although some trials did not meet their primary endpoints. Neri noted, "We remain committed to the bigger indication... and we ...
• Financial Health and Cash Position — The company reported a strong cash position with EUR 380 million in cash equivalents and a net profit of EUR 230 million for 2025. CFO Laura Baldi mentioned, "We will not have an explosion of cost... we will not have an ...
• Pipeline Expansion — Philogen's pipeline continues to grow with new trials launched in 2026, particularly in oncology. Neri emphasized, "We have a rich pipeline and a very good ratio between the cash in the bank spending and expected revenue...

Read the full Philogen S.p.A. transcript (March 30, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 11 Philogen S.p.A. earnings call transcripts on record, spanning October 2, 2023 to September 25, 2026. Based on this history, Philogen S.p.A. reports quarterly. The most recent call on file is dated September 25, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PHIL

Exchange

BIT

Country

IT

Sector

Health Care

Industry

Biotechnology

Calls on record

11

First call

October 2, 2023

Most recent

September 25, 2026

Reporting cadence

quarterly